Targeted Treatment | REZLIDHIA® (olutasidenib) capsules
REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back or has not improved after previous treatment (s). Your healthcare provider will perform a test to make sure that REZLIDHIA is right for you.
新药 | 美国FDA 批准 Olutasidenib 用于IDH1突变的急性髓性白血病 …
2022年12月1日，美国食品和药品管理局（FDA）批准了 Olutasidenib（Rezlidhia）上市，该药可用于治疗成人复发或难治性（R/R）急性髓细胞白血病（AML），且患者通过FDA批准的试验检测到易感异柠檬酸脱氢酶-1（IDH1…
FDA approves olutasidenib for relapsed or refractory acute …
On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a...
IDH1突变复发性AML又一新药：Rezlidhia(olutasidenib)在美获批
2022年12月6日 · 近日，美国FDA批准了Rigel制药的Rezlidhia(olutasidenib)胶囊用于患有敏感性IDH1突变的复发性或难治性急性髓性白血病(AML)成人患者，该突变由雅培的RealTime IDH1 Assay检测。
REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an...
Olutasidenib - Wikipedia
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. [2] [3] Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. [2] It is taken by mouth. [2]
Transform Your Expectations | REZLIDHIA® (olutasidenib) capsules
REZLIDHIA is for adults with mIDH1+ relapsed or refractory acute myeloid leukemia (AML). Please see Full Prescribing Information, including Boxed WARNING.
FDA D.I.S.C.O. Burst: Rezlidhia
2023年1月10日 · On December 1, 2022, the FDA approved olutasidenib (brand name Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as...
Drug Trials Snapshots: REZLIDHIA - FDA
REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back...
Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) …
2022年12月1日 · REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.